HOME >> MEDICINE >> NEWS
Best treatment for mild or moderate depression unclear

Guidelines for the management of mild or moderate depression are unclear because firm evidence is lacking, claim doctors in this week's BMJ.

The National Institute for Clinical Excellence (NICE) provides clear guidance on the treatment of moderate to severe depression, but what is less clear is the appropriate treatment for mild to moderate depression, write Gene Feder and colleagues.

They say that the study on which the guidelines are based identifies evidence supporting problem solving therapies and counselling, but evidence on other interventions is weak or absent.

Although these shortcomings are acknowledged, the guidelines offer limited advice on how to determine whether or not a particular patient may benefit from treatment, they add.

They suggest that we need a better understanding of the interaction that occurs when individuals seek medical help for an emotional problem. "This medicalisation of unhappiness would benefit from sociological as well as clinical research," they conclude.


'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ-British Medical Journal
3-Feb-2005


Page: 1

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. Chronic pain treatments more effective when taken together, new study shows
3. Brain activity prior to treatment flags vulnerability to antidepressant side effects
4. Cultural and social factors influence prostate cancer treatment
5. Research offers hope of new treatments for liver damage
6. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
7. Stanford patient is first to test new treatment for peripheral arterial disease
8. Scientist works on innovative treatments for brain tumors
9. Blacks less likely to get expensive, newer heart treatments
10. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
11. Study examines lessons learned at Africas first public antiretroviral treatment clinic

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Best treatment for mild moderate depression unclear

(Date:5/24/2013)... News) -- Drugs commonly used to treat glaucoma may ... interfere with vision, according to a new study. ... used to reduce eye pressure, have already been shown ... color, the researchers said, suggesting that the new findings ... Doctors should be conservative when prescribing these drugs, the ...
(Date:5/24/2013)... Let’s face it: very few are luckily ... the majority of people to be uncomfortable with the color ... coffee addiction or simply genetics, yellowish or stained teeth suppresses ... , Herald Square Dental is proud to announce ... Venus White Max. , Teeth become discolored for a ...
(Date:5/24/2013)... Chino, CA (PRWEB) May 24, 2013 Area ... huge selection of new hot tubs to choose from at ... Super Sale . The sales event takes place at ... May 26, 2013. , Jacuzzi, the industry's leading hot ... sale traveling across the country. The event will feature popular ...
(Date:5/24/2013)... New York (PRWEB) May 24, 2013 ... lawsuit involving Intuitive Surgical Inc.’s da Vinci Surgical ... to court records, a Washington State Court jury ruled ... negligence in training a surgeon who performed a da ... later. The patient’s family had alleged in their ...
(Date:5/24/2013)... development of infantile myofibromatosis (IM)a disorder characterized by multiple ... new therapeutic targets, according to researchers from the Icahn ... in the American Journal of Human Genetics , ... disease, for which the only current treatment option is ... an inheritied disorder that develops in infancy or even ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2
(Date:5/23/2013)... SAN DIEGO y PARÍS, 24 de ... VOLC ), un destacado desarrollador y fabricante ... para mejorar la diagnosis y tratamiento de la ... resultados preliminares del ensayo ADVISE ( Ad enosine ... tenosis E valuation) II durante la sesión ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
Cached News: